Press Releases

Press Releases

Date Title
October 17, 2019
CAMBRIDGE, Mass. , Oct. 17, 2019 (GLOBE NEWSWIRE) -- Genocea Biosciences, Inc. (NASDAQ: GNCA), a biopharmaceutical company developing next-generation neoantigen immunotherapies, will host its third quarter 2019 financial results and corporate update conference call and live audio webcast on
September 27, 2019
Additional p ositive   GEN-009 c linical   i mmunogenicity   d ata   d riven by ATLAS™ to be p resented at ESMO Company to present at the Cantor Fitzgerald 2019 Global Healthcare Conference CAMBRIDGE, Mass. , Sept. 27, 2019 (GLOBE NEWSWIRE) -- Genocea Biosciences, Inc.
August 30, 2019
CAMBRIDGE, Mass. , Aug. 30, 2019 (GLOBE NEWSWIRE) -- Genocea Biosciences, Inc. (NASDAQ: GNCA), a biopharmaceutical company developing personalized cancer immunotherapies, today announced that Chip Clark , president and chief executive officer, will present at two leading healthcare conferences in
July 25, 2019
Initiated Part B of Phase 1/2a clinical trial of neoantigen vaccine candidate GEN-009; Plans to present additional GEN-009 immunogenicity data at ESMO 2019 Conference call today at 8:30 am ET CAMBRIDGE, Mass. , July 25, 2019 (GLOBE NEWSWIRE) -- Genocea Biosciences, Inc.
July 18, 2019
CAMBRIDGE, Mass. , July 18, 2019 (GLOBE NEWSWIRE) -- Genocea Biosciences, Inc. (NASDAQ: GNCA), a biopharmaceutical company developing personalized cancer immunotherapies, will host its second-quarter 2019 financial results and corporate update conference call and live audio webcast on Thursday,
June 19, 2019
CAMBRIDGE, Mass. , June 19, 2019 (GLOBE NEWSWIRE) -- Genocea Biosciences, Inc . (NASDAQ: GNCA), a biopharmaceutical company developing personalized cancer immunotherapies, today announced the pricing of its previously announced underwritten public offering of 10,500,000 shares of its common stock
June 18, 2019
CAMBRIDGE, Mass. , June 18, 2019 (GLOBE NEWSWIRE) -- Genocea Biosciences, Inc . (NASDAQ: GNCA), a biopharmaceutical company developing personalized cancer immunotherapies, today announced that it has commenced an underwritten public offering of 10,000,000 shares of its common stock.
June 3, 2019
    Post-vaccination T cell responses detected to 91% of vaccine neoantigens, including CD8 + T cell responses to 53% of vaccine neoantigens Conference call and webcast to discuss results TODAY at 8:30 am ET CAMBRIDGE, Mass. , June 03, 2019 (GLOBE NEWSWIRE) -- Genocea Biosciences, Inc .
May 31, 2019
Poster presentation tomorrow, June 1 st at 8:00 am CT in Poster Hall A Conference call and webcast to discuss results Monday, June 3 rd at 8:30 am ET CAMBRIDGE, Mass. , May 31, 2019 (GLOBE NEWSWIRE) -- Genocea Biosciences, Inc . (NASDAQ: GNCA), a biopharmaceutical company developing personalized
May 16, 2019
CAMBRIDGE, Mass. , May 16, 2019 (GLOBE NEWSWIRE) -- Genocea Biosciences, Inc . (NASDAQ: GNCA), a biopharmaceutical company developing personalized cancer immunotherapies, today announced a research collaboration with Iovance Biotherapeutics, Inc. to assess the potential of applying Genocea’s
May 16, 2019
Post-vaccination immune responses detected to 93% of vaccine neoantigens  in first three patients analyzed Additional data to be presented June 1 st at ASCO 2019 and discussed on a conference call and webcast on June 3 rd CAMBRIDGE, Mass. , May 16, 2019 (GLOBE NEWSWIRE) -- Genocea Biosciences, Inc
April 30, 2019
Company anticipates presenting first GEN-009 immunogenicity data at ASCO 2019 Conference call today at 9:00 am ET CAMBRIDGE, Mass. , April 30, 2019 (GLOBE NEWSWIRE) -- Genocea Biosciences, Inc . (NASDAQ: GNCA), a biopharmaceutical company developing personalized cancer immunotherapies, today
April 23, 2019
CAMBRIDGE, Mass. , April 23, 2019 (GLOBE NEWSWIRE) -- Genocea Biosciences, Inc. (NASDAQ: GNCA), a biopharmaceutical company developing personalized cancer immunotherapies, will host its first-quarter 2019 financial results and corporate update conference call and live audio webcast on Tuesday,
April 3, 2019
CAMBRIDGE, Mass. , April 03, 2019 (GLOBE NEWSWIRE) -- Genocea Biosciences, Inc. (NASDAQ: GNCA), a biopharmaceutical company developing personalized cancer immunotherapies, today announced that Chip Clark , president and chief executive officer, will present a corporate overview at the 18 th Annual
April 2, 2019
CAMBRIDGE, Mass. , April 02, 2019 (GLOBE NEWSWIRE) -- Genocea Biosciences, Inc. (NASDAQ: GNCA), a biopharmaceutical company developing neoantigen cancer immunotherapies, today announced the presentation of data from ATLAS™, its ex vivo platform for comprehensively profiling patients’
March 6, 2019
CAMBRIDGE, Mass. , March 06, 2019 (GLOBE NEWSWIRE) -- Genocea Biosciences, Inc. (NASDAQ: GNCA), a biopharmaceutical company developing personalized cancer immunotherapies, today announced that Chip Clark , president and chief executive officer, will present a corporate overview at the Cowen &
February 28, 2019
Company advancing lead clinical-stage neoantigen cancer vaccine candidate and expanding pipeline into adoptive cell therapy Diantha Duvall to join as CFO, bringing broad life science financial leadership experience Conference call today at 9:00 am ET CAMBRIDGE, Mass. , Feb.
February 21, 2019
CAMBRIDGE, Mass. , Feb. 21, 2019 (GLOBE NEWSWIRE) -- Genocea Biosciences, Inc. (NASDAQ: GNCA), a biopharmaceutical company developing personalized cancer immunotherapies, today announced that it will host a conference call and live audio webcast on Thursday, February 28 at 9:00 am ET to provide a
February 12, 2019
CAMBRIDGE, Mass. , Feb. 12, 2019 (GLOBE NEWSWIRE) -- Genocea Biosciences, Inc. (NASDAQ: GNCA), a biopharmaceutical company developing personalized cancer immunotherapies, today announced that it has entered into a private placement with certain existing and new investors providing for the purchase
January 2, 2019
First immunogenicity data now expected in mid-2019 CAMBRIDGE, Mass. , Jan. 02, 2019 (GLOBE NEWSWIRE) -- Genocea Biosciences, Inc. (NASDAQ: GNCA), a biopharmaceutical company developing personalized cancer immunotherapies, today announced the dosing of the first patients in its Phase 1/2a clinical